



Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: a Collaborative Initiative for Paediatric HIV Education & Research (CIPHER) Global Cohort Collaboration analysis

<u>Kunjal Patel</u>, Colette Smith, Intira Jeannie Collins, Ruth Goodall, Elaine Abrams, Annette Sohn, Thahira Jamal Mohamed, Russell Van Dyke, Pablo Rojo, Kara Wools-Kaloustian, Jorge Pinto, Andrew Edmonds, Irene Marete, Mary Paul, Harriet Nuwaqaba-Biribonwoha, Valériane Leroy, Mary-Ann Davies, and Rachel Vreeman: CIPHER Duration of Second-line Project Team







- 1.8 million are children living with HIV globally
 - 180,000 new infections in 2017
- ART recommended for all children and adolescents
 - 52% of children living with HIV receiving ART
- Few studies evaluating outcomes associated with second-line ART, particularly in resource-limited settings







To describe characteristics at initiation of second-line ART and subsequent immunological and clinical outcomes among children living with HIV globally



Study Population




- Individual level data through 2015 from 11 cohort networks
 - North America
 - Latin America (Caribbean, Central & South America)
 - Europe
 - Asia
 - Southern Africa (South Africa & Botswana)
 - Rest of sub-Saharan Africa (SSA)
- Children aged <10 years at cohort enrollment
 - proxy for perinatal HIV infection
- Age <18 years at initiation of 'standard' combination first-line ART
- ≥1 day of follow-up after switch to second-line ART




Study Definitions



- 'Standard' combination ART: ≥ three drugs, with ≥ 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus either a non-NRTI (NNRTI) or a ritonavir-boosted protease inhibitor (PI)
- Switch to second-line was defined as:
 - change of ≥1 NRTI plus either change in drug class (NNRTI to PI or vice versa) or PI change; or
 - ii. change from single to dual PI; or
 - iii. addition of a new drug class
- AIDS was defined as progression to a WHO Stage 3/4 or CDC Stage
 C clinical diagnosis









Characteristics at start of second-line ART, N(%)	Total (n=3,555)
Female sex	1564 (44.0)
Age (years)	
Median (IQR)	8.4 (5.3, 11.4)
≤5	800 (22.5)
6-9	1484 (41.7)
≥10	1271 (35.8)
Time on first-line ART (years), Median (IQR)	2.8 (1.6, 4.7)
Monitoring Strategy ¹	
Clinical only	126 (3.5)
Routine CD4	575 (16.2)
Routine CD4 + targeted VL	402 (11.3)
Routine CD4 + routine VL	2452 (69.0)

¹Cohort-level variable derived from the frequency and availability of CD4 and VL measures across all ART-treated children





Characteristics at start of second-line ART, N (%)	Total (n=3,555)
AIDS diagnosis	
Prior to start of first line	1450 (40.8)
Between first and second line	333 (9.4)
CD4 count (cells/mm ³)	
N (%)	2786 (78.4)
<200	731 (26.2)
>500	1261 (45.3)
HIV Viral load (copies/ml)	
N (%)	2185 (61.5)
>1000	1783 (81.6)
Weight z-score ¹	
N (%)	2953 (83.1)
Median, IQR	-1.5 (-2.5, -0.5)
1111/ 1000 reference negulation used to calculate a secret	


¹UK-1990 reference population used to calculate z-scores





2nd line regimens after NNRTI-based 1st line

EFV MVP Other NNRTI LPV/r Other PI/r INSTI









2nd line regimens after PI-based 1st line


EFV 💹 NVP 🔳 Other NNRTI 🗖 LPV/r 🚿 Other PI/r 💻 INSTI
















1

0.5

0











Cumulative incidence of loss to follow-up (LTFU)







Summary/Conclusions



- Children with perinatally acquired HIV have responded well to second-line ART with increases in CD4 and low to moderate rates of early LTFU and mortality
- Current generation on second-line ART largely switched before adolescence after less than 3 years on first-line ART
 - Emphasizes importance of providing adherence support for those on first-line ART and those who have already switched to secondline ART
 - Raises concerns about future drug options should the need for third- and fourth-line regimens arise through adolescence and adult life



Second-Line Project Team



Co-chairs: Kunjal Patel and Rachel Vreeman

UCL Data Center: Colette Smith, Ruth Goodall, Intira Jeannie Collins

Members:

- BIPAI (Baylor): Mary Paul
- CCASAnet: Jorge Pinto
- EPPICC: Pablo Rojo Conejo
- IeDEA-Asia-Pacific: Thahira Jamal Mohamed and Annette Sohn
- IeDEA-Central Africa: Andrew Edmonds
- IeDEA-East Africa: Irene Marete and Kara Wools-Kaloustian
- IeDEA-Southern Africa: Mary-Ann Davies
- IeDEA-West-Africa: Valériane Leroy
- PHACS/IMPAACT: Russell Van Dyke
- Optimal Models: Harriet Nuwaqaba-Biribonwoha and Elaine Abrams





Acknowledgements

- International AIDS Society
- CIPHER Steering Committee
- CIPHER Global Cohort Collaboration Oversight Group
- Marissa Vicari CIPHER Manager
- CIPHER Data Centers
 - UCT-CIDER (Mary-Ann Davies)
 - UCL-MRC (Ali Judd)
 - HSPH-PHACS DOC (George Seage)
- Networks
 - BIPAI, CCASAnet, EPPICC, IeDEA-Asia Pacific, IeDEA-Central Africa, IeDEA-East Africa, IeDEA-Southern Africa, IeDEA-West Africa, IMPAACT, PHACS, Optimal Models